The article, titled 'Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study,' highlights the clinically meaningful efficacy and safety profile of Lipella's lead product candidate, LP-10 as a potential treatment for hemorrhagic cystitis.
Dr.
Clinical Trial Highlights
Lipella's multi-center, dose-escalation study was led by Dr.
13 patients with moderate to severe refractory hemorrhagic cystitis were treated with up to two courses of LP-10 intravesical bladder instillations.
Pharmacokinetic analysis demonstrated a very short duration of systemic uptake and symptomatic improvements including: decreased hematuria, decreased cystoscopic bleeding, a reduced number of ulceration sites, and, improved urinary symptoms.
ABOUT HEMORRHAGIC CYSTITIS
Hemorrhagic cystitis is a disease with great unmet need and no currently approved drug treatment. Radiation used to treat various cancers can cause chronic, painful urinary inflammation and blood loss, known as radiation hemorrhagic cystitis. Certain chemotherapies can also cause this painful form of urinary bleeding. The blood loss associated with hemorrhagic cystitis can lead to surgery and can be fatal. There are currently no adequate therapies available for the treatment of moderate to severe hemorrhagic cystitis patients.
ABOUT
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in
Forward-Looking Statements
This press release includes certain 'forward-looking statements.' All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as 'may,' 'will,' 'could,' 'continue,' 'would,' 'should,' 'potential,' 'target,' 'goal,' 'anticipates,' 'intends,' 'plans,' 'seeks,' 'believes,' 'estimates,' 'predicts,' 'expects,' 'projects' and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other factors. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future.
Contact:
Dr.
Email: Info@Lipella.com
Tel: 1-412-894-1853
(C) 2023 Electronic News Publishing, source